Drug Combination Details
| General Information of the Combination (ID: C50254) | |||||
|---|---|---|---|---|---|
| Name | Morusin NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | ||
| LN-18 | CVCL_0392 | Glioblastoma | Homo sapiens | |||
| Experimental
Result(s) |
Morusin induces TRAIL sensitization by regulating EGFR and DR5 in human glioblastoma cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells. J Nat Prod. 2016 Feb 26;79(2):317-23. | |||
